In This Issue...

4. Pantoprazole 40mg tablets (Pantoloc®)
   - Proton pump inhibitor for the management of various gastrointestinal disorders including reflux esophagitis, peptic ulcer disease and *Helicobacter pylori* infection
   - Omeprazole MUPS 20mg will still be retained on formulary for nasogastric or other tube administration

Deletions

1. Apraclonidine 0.5% eye drops (Iopidine®)
   - Alternative: Brimonidine 0.2% eye drops
   - Both brimonidine and apraclonidine are alpha-2 agonists used to lower intraocular pressure in patients with ocular hypertension and open-angle glaucoma
   - Brimonidine is as efficacious as apraclonidine, but better tolerated (lower incidence of local allergic reactions and tachyphylaxis), and less expensive

Changes to Formulary

Additions

1. Iron Sucrose injection (Venofer®)
   - Intravenous iron product to be used in patients intolerant to iron dextran
   - See page 3 for drug review

2. Dalteparin injection (Fragmin®)
   - Low-molecular-weight heparin for the prophylaxis and management of deep vein thrombosis (DVT)
   - Alternative to adjusted dose warfarin for the prophylaxis of DVT following hip surgery
   - See page 4 for drug review

3. Mycophenolate injection (Cellcept®)
   - Immunosuppressive agent used in the prevention of rejection in solid organ transplant patients

Deletions

1. Apraclonidine 0.5% eye drops (Iopidine®)
   - Alternative: Brimonidine 0.2% eye drops
   - Both brimonidine and apraclonidine are alpha-2 agonists used to lower intraocular pressure in patients with ocular hypertension and open-angle glaucoma
   - Brimonidine is as efficacious as apraclonidine, but better tolerated (lower incidence of local allergic reactions and tachyphylaxis), and less expensive
Updated Policies/Procedures

1. New Hospital Bowel Protocol Policy

Phase 1: VGH Acute Care Units
Over the years, many patient care areas have developed their own bowel protocols which resulted in having over 30 different protocols in use at VGH. Much effort has been expended in consolidating these into 17 pre-printed orders (PPO).

Effective April 1, 2002, if a prescription is simply written for “Bowel Protocol” it will be interchanged with the appropriate protocol using a PPO in accordance with the patient location. The pharmacy will enter the order into PCIS and send a copy to the unit for the physician to sign. If this bowel protocol is unsuitable or there is no existing PPO for a specific location, the physician may choose an alternative PPO or write specific medication orders for the patient (including dose, form & frequency).

The following is a list of the current hospital pre-printed Bowel Protocols available, along with the page number required to order a supply from the Printing department. Having the orders available on the units will enable the physicians to select the desired protocol at the time of prescribing.

<table>
<thead>
<tr>
<th>Bowel Protocol</th>
<th>PPO Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burns</td>
<td>2</td>
</tr>
<tr>
<td>Burns Pediatric</td>
<td>1</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>70</td>
</tr>
<tr>
<td>ENT</td>
<td>285</td>
</tr>
<tr>
<td>Liver Transplant</td>
<td>40</td>
</tr>
<tr>
<td>Medicine/Geriatrics</td>
<td>19</td>
</tr>
<tr>
<td>Nephrology</td>
<td>22</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>38</td>
</tr>
<tr>
<td>Orthopedics &amp; Trauma</td>
<td>39</td>
</tr>
<tr>
<td>Orthopedics-Spinal</td>
<td>264</td>
</tr>
<tr>
<td>Palliative Care</td>
<td>71</td>
</tr>
<tr>
<td>Respirology</td>
<td>142</td>
</tr>
<tr>
<td>Renal Transplant</td>
<td>41</td>
</tr>
<tr>
<td>TB Respirology</td>
<td>124</td>
</tr>
<tr>
<td>Thoracic surgery</td>
<td>86</td>
</tr>
<tr>
<td>Urology</td>
<td>500</td>
</tr>
<tr>
<td>Vascular surgery</td>
<td>51</td>
</tr>
</tbody>
</table>

2. Revised Drug Administration Policies

- Vancomycin desired trough (pre-dose) serum levels have been increased to 5-15mg/L (up to 20mg/L for aggressive therapy). Desired peak serum levels (immediate post-dose) are 20-40mg/L (3 hour post-dose level 15-30mg/L).
- Glycoprotein IIb/IIa inhibitors administration has been extended to the Day Bed Area.
- After a bolus test injection of intrathecal baclofen, temperature, pulse, respiratory rate, oxygen saturation and blood pressure must be monitored q30minutes x 2 post injection, then q1h until patient is discharged.

3. Pyxis Implementation at UBC Hospital

Cathy Figura, Pyxis Co-Project Manager, Information Systems
Luciana Frighetto Pyxis Co-Project Manager, Pharm. Sci. CSU

The implementation of an automated dispensing system (ADS) is a major undertaking for a hospital and primarily affects nursing, pharmacy and information systems personnel. The goal of an ADS is improved patient care through an improved medication distribution system. The benefits of such a system in the acute care setting include:

- increased nurse and pharmacist time for direct patient-care activities
- potential for reduced medication errors and
- improved drug inventory management including narcotic system management.

The ADS selected for implementation at the UBC Hospital is Pyxis. Pyxis Medstation dispensing cabinets that resemble “ATMs” have been installed on select patient care areas to offer easy, secure, computer-controlled access to medications. Each dispensing cabinet is connected to a central (host) computer in the pharmacy department that, in turn, is interfaced with the existing hospital computer system.

The first phase of the Pyxis ADS implementation at UBC Hospital was the introduction of the Pyxis Medstations as a night cupboard, ward stock, and narcotic medication distribution system. The system went live over the two-week period of January 21, 2002 to February 01, 2002. On behalf of Clinical Information Systems and Pharmaceutical Sciences CSU, we would like to thank all the nurses at UBC Hospital for their patience and support during the project's development and implementation. Your
participation was instrumental in achieving its successful activation!

In the future, there are plans to implement an ADS at VGH. In addition, the ADS at both sites should be expanded to access all patient medication from the Pyxis Medstations in order to achieve all the benefits of this system.

New Drug/Drug Products

1. Iron Sucrose Injection (Venofer®)
   Karen Shalansky, Pharm.D., FCSHP

Parenteral iron products are indicated in patients with iron deficiency anemia when the oral route is not feasible due to intolerance or malabsorption, or severe iron deficiency where a rapid therapeutic response is desired. The administration of erythropoietin to patients with end-stage renal disease has also increased the demand for parenteral iron administration. A new product, iron sucrose, has been added to formulary at VHHSC.

Comparison to Iron Dextran

Until recently, iron dextran has been the only form of intravenous iron available in Canada. Iron dextran is, however, associated with a variety of adverse reactions, including pruritis, rash, abdominal pain, flank pain, arthralgias, myalgias, fever, hypotension, pulmonary edema, wheezing, stridor, and angioedema. In a review of 573 uremic patients, the overall incidence of adverse reactions to iron dextran was 4.7% over a 2 year period. Of these, 0.7% were considered serious anaphylactoid reactions. An initial intravenous test dose of iron dextran 25mg is required to determine tolerability even though less than 20% of all adverse reactions occur with the test dose. Intolerance to iron dextran is thought to be due to the dextran portion of the complex and not to the iron itself.

Iron sucrose offers improved tolerability compared to iron dextran. Reported adverse effects appear to be infrequent and non-life threatening (metallic taste, headache, nausea/vomiting, muscular pain, pruritis, pyrexia). In a trial of 23 hemodialysis patients with documented allergy to iron dextran, all patients were successfully switched to iron sucrose. Iron dextran allergies were classified as a) mild reactions (n=16): urticaria, pruritis, back pain or b) severe anaphylactoid reactions (n=7): dyspnea, wheezing, hypotension, angioedema. All patients were switched to iron sucrose (no test dose) given as either 100mg IV push over 5 minutes (n=184 doses) or IV infusion over 1 hour (n=39 doses). Only 2 mild reactions were reported: metallic taste and rate-related pruritis.

Iron sucrose has been studied in several populations with iron deficiency, although primarily in patients with renal disease. Three trials assessing a total of 183 pre-dialysis and hemodialysis patients found no immediate or delayed reactions with 1000mg given in divided doses over several weeks. Test doses were not employed in any of these studies.

Dosage and Administration

The dosage of iron sucrose is 1000mg total dose divided into thrice weekly to monthly increments of 100-500mg. Compared to iron dextran, the drug can be administered over a shorter period of time. Doses of 100mg or less can be given over 15-30 minutes, 200-250mg over 1-2 hours and doses up to 500mg over 3-4 hours. In comparison, iron dextran 100mg should be administered over at least 1 hour and higher doses (to a maximum of 1000mg) over a more prolonged period of 3-8 hours. A test dose of iron sucrose is not required, which alleviates both nursing and physician time.

Cost Comparison

<table>
<thead>
<tr>
<th>Drug</th>
<th>Strength</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron Dextran (Infufere®)</td>
<td>100mg/2mL</td>
<td>$15.50/100mg</td>
</tr>
<tr>
<td>Iron Sucrose (Venofer®)</td>
<td>100mg/2mL</td>
<td>$37.00/100mg</td>
</tr>
</tbody>
</table>

Conclusion

Iron sucrose should be used as an alternative to intravenous iron dextran in those patients who are intolerant to the dextran molecule. Although more costly, the sucrose formulation offers improved tolerability, no test dose requirement, and faster rate of infusion.

References

2. Dalteparin (Fragmin®)
Rubina Sunderji, Pharm.D., FCSHP

Dalteparin is indicated for prevention of deep vein thrombosis (DVT) in general and hip surgery, treatment of DVT and acute coronary syndromes (ACS), and prevention of clotting in the extracorporeal system during hemodialysis and hemofiltration in conjunction with renal failure.¹

**Pharmacology**
Dalteparin, like other low molecular weight heparins (LMWH), exerts its anticoagulant effect by activating antithrombin III. Unlike unfractionated heparin (UFH), LMWH have greater activity against factor Xa than against thrombin (factor IIa). For dalteparin, the ratio of anti-Xa to anti-IIa activity is 2.7:1. The importance of factor Xa relative to thrombin inhibition in mediating antithrombotic effects of LMWH is unclear but there is evidence that both are necessary.²

Compared to UFH, LMWH produce a more predictable anticoagulant response reflecting their better bioavailability, longer half-life and dose-independent clearance.²³ As a result, LMWH are more convenient to use because of the ease of once or twice daily subcutaneous administration and the lack of need for laboratory monitoring of anticoagulant effect.³

The onset of action of LMWH following subcutaneous administration is immediate.⁴ The peak inhibitory effect of dalteparin on plasma anti-Xa levels occurs within 4 hours.³ The primary route of dalteparin elimination is renal and the drug has a serum elimination half-life of 119 to 139 minutes.²³ Guidelines for dosage adjustment in renal failure are not available and, therefore, monitoring of anti-Xa levels is recommended in severe renal failure.

**Clinical Trials of DVT Prophylaxis in Orthopedics**

**Total hip replacement (THR):** Current guidelines for pharmacotherapy of DVT prophylaxis in THR include LMWH or low intensity warfarin (target INR range 2-3).⁵ Adjusted dose heparin is also acceptable but is not preferred as it is a cumbersome and complex method.

Previous studies comparing warfarin and various LMWH started 12-24h post-operatively have shown similar efficacy.⁵ While pre-operative initiation of LMWH has shown to be superior to warfarin, there is concern for increased bleeding risk.⁶ The recent North American Fragmin trial (NAFT) is the first randomized, double-blind trial showing superiority of a LMWH, dalteparin, over warfarin when started early post-op.⁷ The initial dose was 2500IU 4-6 hours post-op, followed by 5000IU daily. The use of an initial lower dose post-op was associated with equivalent bleeding risk to warfarin (6.5% vs 4.5% with warfarin).

Current guidelines recommend at least 7 to 10 days of anticoagulation prophylaxis post-THR.⁵ In a concurrent study, the NAFT investigators showed dalteparin to be significantly more effective when continued beyond hospital discharge for a mean of 35 days post-THR.⁸ This result was in comparison to in-hospital warfarin prophylaxis followed by placebo post-hospital discharge. Prolonged dalteparin treatment reduced venographically detected total and proximal DVT rates by more than 50% (total DVT: placebo 10.5%, dalteparin 4.8%, p=0.03; proximal DVT: placebo 4.8%, dalteparin 1%, p=0.02). Until the economic implications are known, extended out-of-hospital LMWH is currently recommended for high-risk patients.⁵

Total knee replacement (TKR): Current guidelines for pharmacotherapy of DVT prophylaxis in TKR include LMWH or low intensity warfarin (target INR range 2-3) although pooled analyses suggest superiority of LMWH.⁵ There are no published head-to-head comparisons of dalteparin with warfarin or with other LMWH in the TKR population. Enoxaparin remains the LMWH for DVT prophylaxis in TKR.

**Trauma:** LMWH is the preferred method of DVT prevention in trauma patients. As studies with dalteparin are lacking in these patients, enoxaparin will continue to be used for this indication.

**Clinical Trials of DVT Treatment**

There are 4 studies comparing dalteparin with UFH for the treatment of DVT. Patients with known pulmonary embolism (PE) were excluded. Dalteparin was administered in doses of 200 IU/kg SC once daily in 3 studies and as 120 IU/kg SC twice daily in an earlier smaller scale study. All studies showed dalteparin to be as effective and safe as UFH in the initial management of DVT.⁹-¹²

Only one published study has compared dalteparin to UFH in the initial treatment of symptomatic, submassive PE.¹³ In this pilot study (n=60), UFH was administered by continuous infusion to maintain an aPTT of 2-3x control while dalteparin was given.
subcutaneously at 120IU/kg twice a day, doses higher than those used in studies of DVT treatment. Oral anticoagulation was started on day 7 in both groups and continued for at least 3 months. No patient in either group experienced the primary outcome of recurrent PE within the first 10 days of therapy. There was no major bleeding in either group during the 10-day study period. Of the 48 patients who completed follow up at 3 months, none had shown clinical signs of recurrent PE or new perfusion lung scan defects.

Of note, dalteparin does not have an official indication for treatment of PE and the correct dosage for this indication is unclear since different dosages have been used in other non-comparative studies (200IU/kg/day or 120IU/kg q12h).^{14-18}

**Comparison with Formulary Agents**
The current formulary LMWH at VH are enoxaparin and tinzaparin. Table 1 compares dosage and cost of these agents with dalteparin. Prefilled syringes are available for dalteparin in both 2500IU and 5000IU to enable administration of both the initial half-dose and full dose for DVT prophylaxis.

### Table 1. Dose and Cost Comparison of LMWHs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose for DVT Prophylaxis (Orthopedics)</th>
<th>Dose for DVT Treatment</th>
<th>Cost*/5day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tinzaparin</td>
<td>n/a</td>
<td>175IU/kg SC daily</td>
<td>P: n/a T: $98.00</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>30mg SC bid</td>
<td>1mg/kg SC bid OR 1.5mg/kg SC daily</td>
<td>P: $55.00 T: $105.00-140.00</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>2500IU SC 6 hrs post-op, then 5000IU SC qam</td>
<td>200 IU/kg SC daily OR 100IU/kg SC bid</td>
<td>P: $33.75 T: $105.00</td>
</tr>
</tbody>
</table>

*VH acquisition cost based on dose/70kg patient
n/a = not applicable; P = prophylaxis; T = treatment

**Conclusion**
Dalteparin was recently added to formulary for preferential use in DVT prophylaxis post-THR. This drug will also be available for other approved indications including treatment of DVT. Enoxaparin will be retained on formulary for DVT prevention post-TKR, multiple trauma and spinal cord injury, as well as management of ACS, DVT and PE. The usage of tinzaparin will be reassessed in 3-6 months for potential deletion from formulary.

### References

### Pharmacy Awards
Several members of Pharmaceutical Sciences CSU were recipients of Canadian Society of Hospital Pharmacists (CSHP) 2001 national competitive research awards for excellence:

**Pharmacist utilization of the DIE test to assess aminoglycoside vestibular toxicity.** Denise Carr, Karen Shalansky, Fawziah Marra, Art Malinson (CSHP/Glaxo Wellcome - Pharmaceutical Care).

**Patient preferences in an outpatient parenteral antibiotic therapy program.** Amy Wai, Carlo Marra, Luciana Frighetto, Peter Jewesson (CSHP/Novartis - Pharmacoeconomics).
Adverse Drug Reaction Report 2001

There were a total of 24 suspected adverse drug reactions (ADRs) reported at VHHSC in 2001 (Table 1). Of note, 6 reactions were considered to have been the cause of hospitalization. The continued reporting of all suspected ADRs by nurses, physicians and pharmacists aids in an improved assessment of the magnitude and nature of adverse events. To notify Pharmacy of an ADR, either fill out a yellow ADR alert card, available on all nursing units, and send to Pharmaceutical Sciences CSU, or call local 62481 (VGH site) or local 27249 (UBC site). Pharmacists complete all ADR report forms and forward copies to the B.C. Regional ADR Centre. This Centre does preliminary analysis of the data and then forwards all reports to the Canadian ADR program in Ottawa who then forward them to the World Health Organization.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Suspected ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>Erythema multiforme(^a) (1)</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Torsade de pointes (1)</td>
</tr>
<tr>
<td>Eptifibatide</td>
<td>Thrombocytopenia (1)</td>
</tr>
<tr>
<td>Heparin Infusion</td>
<td>Thrombocytopenia (1)</td>
</tr>
<tr>
<td>Hepatitis B Vaccine (Engerix(^b))</td>
<td>Headache (1); fever, headache, dizziness (1)</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>Upper GI bleed(^a) (1)</td>
</tr>
<tr>
<td>Iron Dextran Infusion</td>
<td>Hives, urticaria (2); back pain (1); Hypotension (2)</td>
</tr>
<tr>
<td>Iron Polysaccharide (Niferex(^b))</td>
<td>Hives, itchy rash over body including neck, face and scalp (1)</td>
</tr>
<tr>
<td>Ketorolac oral</td>
<td>GI bleed(^a) (1)</td>
</tr>
<tr>
<td>Losartan</td>
<td>Cough (1)</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Tonic-clonic seizure (1)</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Macular rash (1)</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>Diabetic ketoacidosis(^a) (1)</td>
</tr>
<tr>
<td>Rofecoxib</td>
<td>Exacerbation of congestive heart failure(^a) (1); GI bleed(^a) (1)</td>
</tr>
<tr>
<td>Sotalol</td>
<td>Bradycardia and hypotension(^a) (1)</td>
</tr>
<tr>
<td>Sulfamethoxazole-trimethoprim</td>
<td>Morbiliform maculopapular rash (1)</td>
</tr>
<tr>
<td>Terazosin</td>
<td>Acute myopathy of upper and lower extremities (1)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Hypovolemic shock secondary to bleeding duodenal ulcers (1)</td>
</tr>
</tbody>
</table>

\(^a\)hospitalized due to ADR